AKBA CIK: 1517022

Akebia Therapeutics, Inc.

  • United States
  • Healthcare
  • Pharma
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
(positive)
Change from FY21 to FY25
millions USD
FY21:
61.0
FY22:
207
FY23:
120
FY24:
97.0
FY25:
197
(positive)
Change from FY21 to FY25
millions USD
FY21:
−265
FY22:
−80.8
FY23:
−46.3
FY24:
−50.5
FY25:
23.5
(positive)
Change from FY21 to FY25
millions USD
FY21:
−227
FY22:
–
FY23:
–
FY24:
–
FY25:
24.8
(positive)
Change from FY21 to FY25
millions USD
FY21:
−282
FY22:
−94.2
FY23:
−51.9
FY24:
−69.4
FY25:
−3.72
(positive)
Change from FY21 to FY25
millions USD
FY21:
−282
FY22:
−94.2
FY23:
−51.9
FY24:
−69.4
FY25:
−5.35

All amounts in millions USD Data sources:SEC EDGARTwelve Data